A Pilot Study of Low-Dose Daunorubicin in Patients With Relapsed/Refractory Acute Leukemia
A Pilot Study of Low-Dose Daunorubicin in Patients With Relapsed/Refractory Acute Leukemia is a PHASE1 clinical asset sponsored by Tara Lin in Acute Lymphocytic Leukemia, Acute Myeloid Leukemia. SEO and diligence focus: Daunorubicin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Acute Lymphocytic Leukemia
Modality: small molecule
Target: Daunorubicin
Sponsor: Tara Lin
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 24, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Daunorubicin
View original source fields
Condition raw: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia
Condition normalized: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Daunorubicin
Target normalized: Daunorubicin